Article
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
Leukemia & lymphoma - 1 Jul 2014
Poiré Xavier, Moser Barry K, Gallagher Robert E, Laumann Kristina, Bloomfield Clara D, Powell Bayard L, Koval Gregory, Gulati Kabir, Holowka Nicholas, Larson Richard A, Tallman Martin S, Appelbaum Frederick R, Sher Dorie, Willman Cheryl, Paietta Elisabeth, Stock Wendy
Abstract excerpt
The addition of arsenic trioxide (ATO) to frontline therapy of acute promyelocytic leukemia (APL) has been shown to result in significant improvements in disease-free survival (DFS). FLT3 mutations are frequently observed in APL, but its prognostic significance remains unclear. We analyzed 245 newly diagnosed adult patients with APL treated on intergroup trial C9710 and evaluated previously defined biological and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
